Processa Pharma에 대한 매도 수량은 투자자에게 Processa Pharma의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Processa Pharma (NASDAQ:PCSA) 주식, 공매도 수량 보고

Processa Pharma

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

ANGO

BIGC

LEVI

PCSA

목요일 아침 (현지 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 1. 월스트리트는 컨스텔레이션 브랜드(NYSE:STZ)가 분기 이익을 주당 4.08달러, 매출 29억 달러로 발표할 것으로 예상하고 있다. 컨스텔레이션 주식은 애프터 마켓에서 0.3% 하락한 254.90달러로 거래되고 있다.

목요일 주목해야 할 주식: 컨스텔레이션 브랜드, 리바이 스트라우스 그리고 3종목

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals Inc

SpaceX COO Gwynne Shotwell said on Friday that the company is building 50-60 satellites per week as it builds its <a href="https://www.benzinga.com/topic/starship">Starlink satellite network</a> in low-earth orbit.
What Happened: Starlink has launched over <a href="https://www.benzinga.com/news/24/09/40744852/elon-musks-spacex-rockets-past-new-milestone-launches-7-000th-starlink-satellite">7,000 Starlink satellites</a> to low-Earth orbit to date. According to data from astronomer Jonathan McDowell, SpaceX has launched over 7000 Starlink satellites into space, of which nearly 6000 are in operational orbit.
Shotwell said on Friday at the conference hosted by Baron Capital that the company will make &#8220;some money&#8221; on Starlink this year. Starlink is the satellite internet segment of SpaceX. It achieved a <a href="https://www.benzinga.com/news/23/11/35583773/spacex-ceo-elon-musk-says-starlink-business-has-achieved-breakeven-cash-flow-is-an-ipo-on-the-cards">breakeven cash flow</a> in November 2023. 
&#8220;We are going to make some money on Starlink this year. But ultimately I think Starship will be the thing that takes us over the top as one of the most valuable companies,&#8221; she said. However, Shotwell refused to divulge more of the company&#8217;s financials. 
The sixth test flight of Starship is now targeted to launch on Tuesday at around 4:00 p.m. CT. For the test flight, the company aims to catch Starship&#8217;s booster back at the launch site as on the last flight and splash down the upper stage in the Indian Ocean. The ambitious launch vehicle is yet to carry any payload to space.
According to a recent report, SpaceX is preparing to initiate a tender offer <a href="https://www.benzinga.com/24/11/42022150/spacex-to-launch-tender-offer-valuing-company-at-over-250-billion-report">valuing the company at over $250 billion</a>. In June, the company was reportedly set for a <a href="https://www.benzinga.com/news/24/06/39516906/elon-musks-spacex-set-for-record-210b-valuation-in-tender-offer-but-still-valued-less-than-tiktok-re" target="_blank" rel="noreferrer noopener">record $210 billion</a> valuation in a tender offer, surpassing its previous $200 billion estimate.
Investor Take: Ron Baron, founder of Baron Capital, said on Friday that his company started investing in SpaceX in 2017 and has since made seven times the money. 
&#8220;We have made 7x our money (since 2017); We continue investing in every one of their offerings. We think we&#8217;ll make 15x our money again over the next 15 years. Elon believes our goals are very conservative to his goals,&#8221; Baron said. 
SpaceX is a privately held company. Unlike Musk&#8217;s publicly held EV company Tesla, SpaceX <a href="https://www.benzinga.com/24/11/42022150/spacex-to-launch-tender-offer-valuing-company-at-over-250-billion-report">does not divulge its financials</a> periodically. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/space/24/11/42025066/elon-musks-spacex-delays-starship-test-flight-next-attempt-now-set-for-tuesday" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s SpaceX Delays Starship Test Flight, Next Attempt Now Set For Tuesday</a></li>
</ul>
Photo courtesy: SpaceX

SPACE

Tech

SpaceX's Gwynne Shotwell Sees Starlink Becoming Profitable In 2024, Bets On Starship Making It One Of The Most Valuable Companies Amid Reports Of Tender Offer Valuing It Over $250B

Destiny Tech100 Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXYZ#NYSE">DXYZ</a>) saw a 12.89% rise in its value during Monday&#8217;s premarket after President-elect Donald Trump appointed pro-Starlink Republican Brendan Carr as the new chairperson of the Federal Communications Commission (FCC).
What Happened: The investment firm, Destiny Tech100, primarily focuses on private technology companies, with its largest holding being SpaceX, which constitutes 37.6% of its portfolio. The firm also invests in other space exploration entities like Axiom Space and Relativity Space, but SpaceX remains its most significant asset.
On Sunday, Trump announced Carr&#8217;s appointment, highlighting Carr&#8217;s commitment to free speech and his opposition to regulatory measures that hinder economic growth. Trump stated that Carr would work to eliminate regulatory barriers affecting American innovators and job creators, particularly in rural areas.
See Also: <a href="https://www.benzinga.com/24/11/42010539/whats-going-on-with-palantir-technologies-stock-today?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Palantir Technologies Stock Today?</a>
Carr, known for his support of Elon Musk&#8216;s Starlink, previously criticized the FCC&#8217;s decision to deny nearly $900 million in subsidies to Starlink. He argued that the FCC&#8217;s actions were part of a broader trend of administrative agencies targeting Musk&#8217;s ventures, especially after his acquisition of Twitter (now X), allegedly under President Joe Biden&#8216;s directives.
Why It Matters: The surge in Destiny Tech100&#8217;s stock is part of a broader trend of increased investor interest following Trump&#8217;s recent election victory. The company&#8217;s shares have <a href="https://www.benzinga.com/general/space/24/11/41887127/whats-going-on-with-destiny-tech100-stock-">climbed over 300%</a> in the past week, reflecting heightened market attention. Destiny Tech100 Inc. is a closed-end management investment firm that invests in private technology companies such as SpaceX, OpenAI, and Epic Games.
Last Friday, SpaceX president Gwynne Shotwell quipped that the next four years might see more than 400 Starship launches, as per Bloomberg. Meanwhile, SpaceX is <a href="https://www.benzinga.com/24/11/42022150/spacex-to-launch-tender-offer-valuing-company-at-over-250-billion-report">reportedly preparing to initiate</a> a tender offer next month for the sale of existing shares at $135 each and valuing the company at over $250 billion.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42022100/trump-media-faces-investor-exodus-as-arc-global-slashes-stake-to-nearly-zero-after-court-ruling?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Major Investor In Trump Media Offloads Most Of Its Stake In DJT Stock</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo by Wirestock Creators on Shutterstock

General

DXYZ

This ETF, Which Allows You To Invest In SpaceX, Surges Nearly 13% In Premarket After Trump Appoints Pro-Starlink Brendan Carr

For the full fiscal year 2025, Twist expects Total revenue is expected to be in the range of $367 million to $377 million, growth of 17 to 20 percent year over year, including:
<ul>
<li>SynBio revenue of $142 to $146 million, growth of 15 to 18 percent</li>
<li>NGS revenue of $204 to $209 million, growth of 20 to 24 percent</li>
<li>Biopharma revenue of $21 to $22 million, growth of 5 to 8 percent</li>
</ul>
Gross margin is projected to be approximately 48% for fiscal 2025 with quarterly sequential improvements and 4QFY25 gross margin of 50%
Adjusted EBITDA of approximately $(60) to $(65) million for fiscal 2025

Guidance

Health Care

TWST

Twist Bioscience Expects Fiscal Year 2025 Sales Of $367M-$377M Vs. Consensus Of $371.416M

Biotech

CABA

Cabaletta Bio  Announces Presentation Of Updated CABA-201 Clinical Data At ACR Convergence 2024l; Says Safety Profile suggested Favorable Risk-Benefit With No CRS Or ICANS In Majority Of Patients

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Sutro Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>) with a Buy and maintains $12 price target.

Price Target

Reiteration

Analyst Ratings

STRO

HC Wainwright & Co. Reiterates Buy on Sutro Biopharma, Maintains $12 Price Target

Jones Trading analyst Catherine Novack initiates coverage on Korro Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) with a Buy rating and announces Price Target of $130.

Initiation

KRRO

Jones Trading Initiates Coverage On Korro Bio with Buy Rating, Announces Price Target of $130

For the first quarter, Twist expects: Total revenue of approximately $87 million
<ul>
<li>SynBio revenue of approximately $34 million, growth of 26% year over year</li>
<li>NGS revenue of approximately $48 million, growth of 22% year over year</li>
<li>Biopharma revenue of approximately $5 million</li>
</ul>
Adjusted EBITDA of approximately $(20) million with sequential improvements throughout 2025

Twist Bioscience Expects Q1 2025 Sales Of ~$87M Vs. Consensus Of $84.473M

WIIM

ALDX

Aldeyra Therapeutics shares are trading higher after the FDA accepted its resubmitted new drug application for Reproxalap for the treatment of dry eye disease, prompting the company to announce an expansion of its option agreement with AbbVie.

HCWB

HCW Biologics shares are trading higher after the company entered into an exclusive licensing deal with WY Biotech for immunotherapy development.

Jones Trading analyst Catherine Novack initiates coverage on Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy rating and announces Price Target of $40.

CAPR

Jones Trading Initiates Coverage On Capricor Therapeutics with Buy Rating, Announces Price Target of $40

NIVF

NewGenIvf shares are trading higher after the company inked a binding term sheet with White Lion Capital for a $100 million equity line of credit, expandable to $500 million.

RGNX

REGENXBIO shares are trading higher after the company announced dosing the first patient in its pivotal trial for Duchenne gene therapy.

Buybacks

Globe Life Announces $1.8B Share Repurchase Authorization; Authorization Replaces Previous $1.3B Authorization

Twist Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.70) by 15.71 percent. This is a 27.16 percent increase over losses of $(0.81) per share from the same period last year. The company reported quarterly sales of $84.71 million which beat the analyst consensus estimate of $82.20 million by 3.05 percent. This is a 26.53 percent increase over sales of $66.95 million the same period last year.

Twist Bioscience Q4 2024 GAAP EPS $(0.59) Beats $(0.70) Estimate, Sales $84.71M Beat $82.20M Estimate

HC Wainwright &amp; Co. analyst Ed Arce reiterates Arbutus Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABUS#NASDAQ">ABUS</a>) with a Buy and maintains $5 price target.

ABUS

HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $5 Price Target

Aldeyra Therapeutics Announces FDA Acceptance For Review Of The Resubmitted New Drug Application For Reproxalap In Treatment Of Dry Eye Disease; Based On FDA Acceptance, Co. Announces Expansion Of Option Agreement With AbbVie

CLRB

Cellectar Biosciences' Q3 Cash And Cash Equivalents Of $34.3M Is Expected To Provide Cash Runway Into Q2 2025

Jefferies analyst Maury Raycroft initiates coverage on Erasca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERAS#NASDAQ">ERAS</a>) with a Buy rating and announces Price Target of $6.

ERAS

Jefferies Initiates Coverage On Erasca with Buy Rating, Announces Price Target of $6

HCW Biologics Inc. ("HCWB" or "HCW Biologics"), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, and WY Biotech Co., Ltd., a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell therapies, announced today that they have entered into a worldwide exclusive license agreement to develop and commercialize one of HCWB's product candidates generated with its new drug discovery platform for therapeutic use.
Key terms of the agreement include that WY Biotech has agreed to pay HCWB $7.0 million in an upfront payment, and HCWB is eligible to receive additional significant development milestone payments and double-digit royalties on future product sales. In addition, HCWB will share a substantial portion of the proceeds from a future transaction(s) involving the molecule, if such a transaction occurs. HCWB also has a payment-free, milestone-free, and royalty-free option to recapture the development and commercialization rights of this molecule for the United States, Canada, Central America, and South America (Opt-in Territory) after the conclusion of the Phase 1 clinical trial. WY Biotech is financially responsible for all costs associated with research and development, manufacturing, clinical development, regulatory approval, and commercialization for the molecule. HCWB will be responsible for costs associated with clinical development, regulatory approval, and commercialization in the Opt-in Territory, if HCWB exercises its opt-in rights. Both companies will work cooperatively in the development stage with a global focus for clinical development and partnering.

HCW Biologics Enters Exclusive Licensing Deal with WY Biotech for Immunotherapy Development

Jefferies analyst Surinder Thind initiates coverage on Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) with a Buy rating and announces Price Target of $28.

INGM

Jefferies Initiates Coverage On Ingram Micro Holding with Buy Rating, Announces Price Target of $28

FDA approves Processa Phase 2 study for NGC-Cap, stock rallies 46%

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Processa Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/pcsa-stock-quote/">PCSA</a>) stock is rising higher on Tuesday after the company <a href="https://finance.yahoo.com/news/processa-pharmaceuticals-announces-fda-clearance-120000203.html">posted an update</a> from the Food and Drug Administration (FDA).



The FDA has cleared Processa Pharmaceuticals for its Phase 2 clinical trial Next Generation Capecitabine (NGC-Cap). This is the company&rsquo;s lead product candidate and is designed to treat patients with advanced or metastatic breast cancer.



With this approval, Processa Pharmaceuticals is able to move forward with a clinical trial of NGC-Cap. The company says that it expect to start enrolling patients in this study this quarter.



David Young, president of research and development at Processa Pharmaceuticals, said this about NGC-Cap.




&ldquo;We previously demonstrated in our Phase 1b study that NGC-Cap is more potent than monotherapy capecitabine, providing up to 5-10 times more 5-fluorouracil exposure to cancer cells. This greater exposure resulted in a greater efficacy, with a safety profile better or similar to existing monotherapy with capecitabine.&rdquo;




<h2>PCSA Stock Movement Today</h2>



With all of this comes heavy trading of PCSA stock today. That has more than 51 million shares changing hands as of this writing. This is a massive surge compared to the company&rsquo;s daily average trading volume of about 90,000 shares.



PCSA stock is up 29.4% as of Tuesday morning.



Investors seeking out even more of the most recent stock market stories are going to want to stick around!



We are offering up insight into all of the hottest stock market news that investors need to know about on Tuesday! A few examples include what&rsquo;s happening with shares of Tesla&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/tsla-stock-quote/">TSLA</a>), Delta&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/dal-stock-quote/">DAL</a>) and SoFi&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sofi-stock-quote/">SOFI</a>) stock today. All of that news is ready to go at the links below!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/tsla-stock-drops-as-tesla-recalls-1-8-million-evs-over-hood-issue/">TSLA Stock Drops as Tesla Recalls 1.8 Million EVs Over Hood Issue</a></li>



<li><a href="https://investorplace.com/2024/07/dal-stock-delta-wants-crowdstrike-to-pay-up-for-flight-delays-caused-by-outage/">DAL Stock: Delta Wants CrowdStrike to Pay Up for Flight Delays Caused by Outage</a></li>



<li><a href="https://investorplace.com/2024/07/sofi-stock-sofi-just-raised-its-profit-guidance-again-whats-going-on/">SOFI Stock: SoFi Just Raised Its Profit Guidance Again. What&rsquo;s Going On?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-processa-pharmaceuticals-pcsa-stock-up-29-today/">Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
2U&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/twou-stock-quote/">TWOU</a>) stock is still rallying higher as a bankruptcy filing has introduced an immense amount of volatility to the online education platform company&rsquo;s shares.



Today&rsquo;s movement has TWOU stock rallying 15.5% as of Tuesday morning. That comes with more than 31 million shares changing hands. For the record, its daily average trading volume is about 2.5 million shares.



The rally today <a href="https://investorplace.com/2024/07/2u-twou-stock-pops-more-than-100-despite-bankruptcy-filing/">follows a surge yesterday</a> that saw the stock jump as more than 100% higher during normal trading hours. It is worth noting that these rallies come after the stock suffered a roughly 60% drop when news of its bankruptcy broke.



<h2>What&rsquo;s Next for 2U Stock?</h2>



2U is using this bankruptcy to <a href="https://investorplace.com/2024/07/twou-stock-alert-2u-plunges-on-ch-11-bankruptcy-filing/">restructure its debt</a> via deals with lenders. This has the company continuing operations throughout the process. It expects to exit bankruptcy by the end of September.



It&rsquo;s also unclear how this bankruptcy filing will affect TWOU stock. While the company is only using it for restructuring, it could cause problems for its listing on the Nasdaq Exchange.



Also, all of this volatility makes TWOU stock a bit of a risky investment. Traders will want to keep that in mind before taking a stake in the company.



Investors will want to stick around for more of the most recent stock market news!



We have all of the hottest stock market stories that traders need to know about on Tuesday! That includes warnings of a potential market crash, why Processa Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/pcsa-stock-quote/">PCSA</a>) stock is up today and more. All of this info is ready to go at the links below!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/a-potential-stock-market-crash-trigger-looms-on-july-31/">A Potential Stock Market Crash Trigger Looms on July 31</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-processa-pharmaceuticals-pcsa-stock-up-29-today/">Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/tsla-stock-drops-as-tesla-recalls-1-8-million-evs-over-hood-issue/">TSLA Stock Drops as Tesla Recalls 1.8 Million EVs Over Hood Issue</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/2u-twou-stock-continues-to-surge-in-bankruptcy-rally/">2U (TWOU) Stock Continues to Surge in Bankruptcy Rally</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

2U (TWOU) Stock Continues to Surge in Bankruptcy Rally

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Processa Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/pcsa-stock-quote/">PCSA</a>) just reported results for the second quarter of 2024.<ul><li>Processa Pharma reported earnings per share of -$1.01. This was below the analyst estimate for EPS of -98 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/pcsa-stock-earnings-processa-pharma-for-q2-of-2024/">PCSA Stock Earnings: Processa Pharma Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PCSA Stock Earnings: Processa Pharma Misses EPS for Q2 2024

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Processa Pharmaceuticals (PCSA – Research Report), H...

Analysts Are Bullish on Top Healthcare Stocks: Processa Pharmaceuticals (PCSA), Healthequity (HQY)

Processa Pharmaceuticals reports GAAP EPS of -$1.01

Processa stock rallies 35% post-market on Phase 2 study update

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Processa Pharmaceuticals (PCSA – Research Report), retaining the price target o...

Buy Rating Affirmed for Processa Pharmaceuticals Amidst Promising Phase 2 Trial for NGC-Cap

Processa Pharmaceuticals GAAP EPS of -$1.03

Processa Pharmaceuticals, Inc. ( ($PCSA) ) has released its Q3 earnings. Here is a breakdown of the information Processa Pharmaceuticals, Inc. pres...

Processa Pharmaceuticals Reports Q3 2024 Financial Results

PSNL

SOFI

TSLA

TWOU

Press Releases

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

Comments

Processa Pharma

매도 수량

Processa Pharma (NASDAQ:PCSA) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌